Form 4: ESSA Pharma CFO David S. Wood Reports Stock Option Grant

ESSA Pharma's Chief Financial Officer, David S. Wood, reported the acquisition of 110,000 stock options.

Summary

• David S. Wood, the Chief Financial Officer of ESSA Pharma Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 25, 2024.
• Wood acquired 110,000 stock options with an exercise price of $9.04.
• These options vest over four years, with 25% vesting one year after the grant date and the remaining 75% vesting in equal monthly installments over the following three years.
• Following the reported transaction, Wood directly owns 110,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Vesting schedules, such as the four-year vesting described in the document, are typical to ensure long-term commitment.
• Comparable companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to work towards increasing shareholder value.
• Employees may see this as a positive sign of investment in leadership.

Key Dates